ReviewCurrent oncology reports2011
Second primary tumors in patients with head and neck cancer.
Review in Current oncology reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- Early detection of esophageal second primary tumors using Lugol chromoendoscopy in patients with head and neck cancer: A systematic review and meta-analysis.Head & neck · 2019Pooled it
- Association Between Oral Cavity Cancer and Lymphoma: A Bidirectional Mendelian Randomization Analysis.Oral health & preventive dentistry · 2026Article
- The Role of Panendoscopy in Primary Diagnostics of Patients with Oral Cavity Cancer.Journal of maxillofacial and oral surgery · 2026Article
- Article
- Decoding the mechanisms behind second primary cancers.Journal of translational medicine · 2025Review
- Prognostic model for overall survival of head and neck cancer patients in the palliative phase.BMC palliative care · 2024Article
- Adjuvant PD-1 antibody in recurrent, previously irradiated oral cavity cancer treated with salvage surgery.Clinical and translational radiation oncology · 2023Article
- Oral Squamous Cell Carcinoma and Concomitant Primary Tumors, What Do We Know? A Review of the Literature.Current oncology (Toronto, Ont.) · 2023Review
- Article
- Concordance, Correlation, and Clinical Impact of Standardized PD-L1 and TIL Scoring in SCCHN.Cancers · 2022Article
- Evaluation of the prevalence of metachronous second primary malignancies in hypopharyngeal carcinoma and their effect on outcomes.Cancer medicine · 2022Article
- Pattern of Recurrence After Platinum-Containing Definitive Therapy and Efficacy of Salvage Treatment for Recurrence in Patients with Squamous Cell Carcinoma of the Head and Neck.Frontiers in oncology · 2022Article
- Article
- Developing a Stacked Ensemble-Based Classification Scheme to Predict Second Primary Cancers in Head and Neck Cancer Survivors.International journal of environmental research and public health · 2021Article
- Screening for synchronous esophageal second primary tumors in patients with head and neck cancer.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2021Article
- Endoscopic near-infrared photoimmunotherapy in an orthotopic head and neck cancer model.Cancer science · 2021Article
- Multiple Primary Malignancies in Head and Neck Cancer: A University Hospital Experience Over a Five-Year Period.Cureus · 2021Article
- Article
- A cause-specific Cox model for second primary tumors in patients with head and neck cancer: A RONCDOC study.Head & neck · 2021Article
- Survival Outcomes in Oral Tongue Cancer: A Mono-Institutional Experience Focusing on Age.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This is a review on second primary tumors in patients with head and neck cancer. These patients have a high risk of developing other cancers simultaneously or subsequently. The incidence of multiple primary tumors in this population can be as high as 27%. Recurrences are the most common cause of treatment failure within the first 2 years of follow-up. After the third year the diagnosis of a second primary tumor becomes the most important cause of morbimortality in head and neck cancer patients, especially in those treated for cancers early diagnosed. Most second primary tumors occur in the upper aerodigestive tract (40%-59%), lung (31%-37.5%), and esophagus (9%-44%). Patients who develop second primary tumor have a significant reduction of survival expectancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.